This has led to the development of humanised monoclonal anti-CD200 antibody ALXN600 used in phase I/II clinical trial (NCT00648739) for patients with CLL and MM with only mild to moderate side effects reported [65]. This evidence concerns the gene CD200 and Miyoshi myopathy.